

OPALE - Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Head :Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 01/23/2015 | Version : 2 | ID : 122

General

Identification

Detailed name Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Sign or acronym OPALE

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL 833542 version 11

General Aspects

Medical area Rheumatology

Health determinants Genetic

Others (details) rheumatoid arthritis

Keywords Rheumatoid arthritis, epidemiology, DMARD, treatments

Scientific investigator(s) (Contact)

Name of the director Bregman

Surname Bruno

Address 3, rue J. Monier - 92500 Rueil Malmaison

Phone +33 (0)1 58 83 60 00

Email bruno.bregman@bms.com

Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname Nathalie

Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

Collaborations

Funding

Funding status	Private
----------------	---------

Details	Bristol-Myers Squibb
---------	----------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb (BMS)
Organisation status	Private

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Random sampling in clusters

Database objective

Main objective	Describe the therapeutic practice used by French rheumatologists in patients suffering from rheumatoid arthritis patients, and describe the treatment patterns used, in a general manner and according to the patients' and disease characteristics.
----------------	--

Inclusion criteria	Register Part: M/F ≥ 18 years, with a mild to severe rheumatoid arthritis currently treated or not treated with either symptomatic agents or DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological), seen in rheumatology clinic visit. Detailed Study Part: patients eligible for the register part, currently treated or initiating a first DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological) at the time of inclusion in the study
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2006
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1600
Data	
Database activity	Data collection completed
Type of data collected	Clinical data

Biological data

Clinical data (detail)

Direct physical measures

Biological data (detail)

ESR, CRP, Rheumatoid factor, HLA DR4, Anti CCP

Presence of a biobank

No

Health parameters studied

Health event/morbidity

Procedures

Data collection method

Paper or electronic form

Participant monitoring

No

Links to administrative sources

No

Promotion and access

Promotion

Link to the document

<http://tinyurl.com/PUBMED-OPALE>

Description

Link to the document

<http://tinyurl.com/HAL-OPALE>

Description

Access

Terms of data access (charter for data provision, format of data, availability delay)

Publications

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only